Yuko Kanbayashi

10PUBLICATIONS
1CO-AUTHORS
PharmacogenomicsPredictive and prognostic markersDisease surveillanceCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 24, 2026
Cardiac adverse events associated with axitinib: A real-world pharmacovigilance study based on the Japanese adverse drug event report database.

|Mar 23, 2026
Predictors of long-term anamorelin hydrochloride use in patients with cancer cachexia: a single-center real-world retrospective study.

Yuko Kanbayashi, Takeshi Ishikawa, Hayato Kawachi

|Feb 03, 2026
Disproportionality analysis of hematologic adverse events associated with trastuzumab deruxtecan using the Japanese pharmacovigilance database.

Yuko Kanbayashi, Risa Morioka, Koichi Takayama

|Oct 08, 2025
Disproportionality Analysis of Pulmonary Adverse Events Associated with Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report Database.

Yuko Kanbayashi, Risa Morioka, Keiko Hosohata

|Sep 02, 2024
Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database.

Yuko Kanbayashi, Sakura Kobayashi, Asuka Kojima

|Apr 26, 2024
Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients.

Yuko Kanbayashi, Eren Tsuchiya, Tadashi Shimizu

Pageof 2

Frequent Collaborators

3 joint publications

Keiko Hosohata